Prognostic Value of SYNTAX Score in Patients With Infarct-Related Cardiogenic Shock: Insights From the CULPRIT-SHOCK Trial.


Journal

JACC. Cardiovascular interventions
ISSN: 1876-7605
Titre abrégé: JACC Cardiovasc Interv
Pays: United States
ID NLM: 101467004

Informations de publication

Date de publication:
25 05 2020
Historique:
received: 28 12 2019
revised: 12 03 2020
accepted: 02 04 2020
entrez: 23 5 2020
pubmed: 23 5 2020
medline: 15 12 2020
Statut: ppublish

Résumé

This study sought to evaluate the prognostic value of the SYNTAX (SYNergy between PCI with TAXUS and Cardiac Surgery) scores in patients undergoing percutaneous coronary intervention (PCI) for multivessel coronary disease with infarct-related cardiogenic shock (CS). The prognostic value of the SYNTAX score in this high-risk setting remains unclear. The CULPRIT-SHOCK (Culprit Lesion Only PCI versus Multivessel PCI in Cardiogenic Shock) trial was an international, open-label trial, where patients presenting with infarct-related CS and multivessel disease were randomized to a culprit-lesion-only or an immediate multivessel PCI strategy. Baseline SYNTAX score was assessed by a central core laboratory and categorized as low SYNTAX score (SS ≤22), intermediate SYNTAX score (22<SS≤32) and high SYNTAX score (SS>32). Adjudicated endpoints of interest were the 30-day risk of death or renal replacement therapy (RRT) and 1-year death. Associations between baseline SYNTAX score and outcomes were assessed using multivariate logistic regression. Pre-PCI SYNTAX score was available in 624 patients, of whom 263 (42.1%), 207 (33.2%) and 154 (24.7%) presented with low, intermediate and high SYNTAX score, respectively. A stepwise increase in the incidence of adverse events was observed from low to intermediate and high SYNTAX score for the 30-day risk of death or RRT and the 1-year risk of death (p < 0.001, for all). After multiple adjustments, intermediate and high SYNTAX score remained strongly associated with 30-day risk of death or renal replacement therapy and 1-year risk of all-cause death. There was no significant interaction between SYNTAX score and the coronary revascularization strategy for any outcomes. In patients presenting with multivessel disease and infarct-related CS, the SYNTAX score was strongly associated with 30-day death or RRT and 1-year mortality.

Sections du résumé

OBJECTIVES
This study sought to evaluate the prognostic value of the SYNTAX (SYNergy between PCI with TAXUS and Cardiac Surgery) scores in patients undergoing percutaneous coronary intervention (PCI) for multivessel coronary disease with infarct-related cardiogenic shock (CS).
BACKGROUND
The prognostic value of the SYNTAX score in this high-risk setting remains unclear.
METHODS
The CULPRIT-SHOCK (Culprit Lesion Only PCI versus Multivessel PCI in Cardiogenic Shock) trial was an international, open-label trial, where patients presenting with infarct-related CS and multivessel disease were randomized to a culprit-lesion-only or an immediate multivessel PCI strategy. Baseline SYNTAX score was assessed by a central core laboratory and categorized as low SYNTAX score (SS ≤22), intermediate SYNTAX score (22<SS≤32) and high SYNTAX score (SS>32). Adjudicated endpoints of interest were the 30-day risk of death or renal replacement therapy (RRT) and 1-year death. Associations between baseline SYNTAX score and outcomes were assessed using multivariate logistic regression.
RESULTS
Pre-PCI SYNTAX score was available in 624 patients, of whom 263 (42.1%), 207 (33.2%) and 154 (24.7%) presented with low, intermediate and high SYNTAX score, respectively. A stepwise increase in the incidence of adverse events was observed from low to intermediate and high SYNTAX score for the 30-day risk of death or RRT and the 1-year risk of death (p < 0.001, for all). After multiple adjustments, intermediate and high SYNTAX score remained strongly associated with 30-day risk of death or renal replacement therapy and 1-year risk of all-cause death. There was no significant interaction between SYNTAX score and the coronary revascularization strategy for any outcomes.
CONCLUSIONS
In patients presenting with multivessel disease and infarct-related CS, the SYNTAX score was strongly associated with 30-day death or RRT and 1-year mortality.

Identifiants

pubmed: 32438990
pii: S1936-8798(20)30876-1
doi: 10.1016/j.jcin.2020.04.003
pii:
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1198-1206

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Paul Guedeney (P)

ACTION Study Group, INSERM UMRS_1166, Institut de cardiologie, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France.

Olivier Barthélémy (O)

ACTION Study Group, INSERM UMRS_1166, Institut de cardiologie, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France.

Michel Zeitouni (M)

ACTION Study Group, INSERM UMRS_1166, Institut de cardiologie, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France.

Marie Hauguel-Moreau (M)

ACTION Study Group, INSERM UMRS_1166, Institut de cardiologie, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France.

Georges Hage (G)

ACTION Study Group, INSERM UMRS_1166, Institut de cardiologie, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France.

Mathieu Kerneis (M)

ACTION Study Group, INSERM UMRS_1166, Institut de cardiologie, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France.

Benoit Lattuca (B)

ACTION Study Group, INSERM UMRS_1166, Institut de cardiologie, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France.

Pavel Overtchouk (P)

ACTION Study Group, INSERM UMRS_1166, Institut de cardiologie, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France.

Stéphanie Rouanet (S)

ACTION Study Group, Statistician Unit, StatEthic, Levallois-Perret, France.

Georg Fuernau (G)

University Heart Center Lübeck, Lübeck, Germany.

Suzanne de Waha-Thiele (S)

University Heart Center Lübeck, Lübeck, Germany.

Uwe Zeymer (U)

Klinikum Ludwigshafen, Institut fur Herzinfarktforschung, Ludwigshafen, Germany.

Marcus Sandri (M)

Heart Center Leipzig, Leipzig Heart Institute, University of Leipzig, Leipzig, Germany.

Ibrahim Akin (I)

First Department of Medicine-Cardiology, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany.

Steffen Desch (S)

Heart Center Leipzig, Leipzig Heart Institute, University of Leipzig, Leipzig, Germany.

Holger Thiele (H)

Heart Center Leipzig, Leipzig Heart Institute, University of Leipzig, Leipzig, Germany.

Gilles Montalescot (G)

ACTION Study Group, INSERM UMRS_1166, Institut de cardiologie, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France. Electronic address: gilles.montalescot@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH